Featured Research

from universities, journals, and other organizations

Better outcome for frozen embryo replacement vs IVF

Date:
February 11, 2013
Source:
Society for Maternal-Fetal Medicine
Summary:
Perinatal outcomes of frozen/thawed embryo replacement better compared to fresh IVF, but worse than non-IVF general population.

In a study to be presented on February 14 at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting ™, in San Francisco, California, researchers will present findings showing perinatal outcomes of frozen/thawed embryo replacement (FER) have better outcomes compared to fresh in vitro fertilization (IVF), but worse outcomes compared to the non-IVF general population.

The study collected data from all IVF treatments in Denmark, Norway and Sweden from 1984 -- 2007, then cross-linked with the Nordic Medical Birth Registries. Babies born after FER (6,653) were compared to those born after fresh IVF (42,287) and the general population (288,868). Researchers looked for eight different outcomes: low birth weight, very low birth weight, preterm birth, very preterm birth, small for gestational age, macrosomia (excessive birth weight), large for gestational age, and stillbirth.

"FER is used increasingly in IVF programs to avoid the risks associated with multiple births," said Ulla-Britt Wennerholm, of Sahlgrenska University Hospital in Göteberg, Sweden. "We sought to analyze the outcomes compared to spontaneous conceptions and fresh IVF."

Dr. Wennerholm and her associates found children born after FER had higher rates of PTB, very PTB, LBW, very LBW, LGA, and macrosomia compared to spontaneous conceptions. However, when compared to fresh IVF births, children born after FER fared better, having lower rates of PTB, LBW, and SGA. But they also found children born after FER to have higher rates of LGA and macrosomia than those born from fresh IVF.

Researchers concluded outcomes for FER to be better compared to fresh IVF, but worse compared to the general population. However, they believe the higher rates of LGA and macrosomia compared to fresh IVF will require further attention.

This study was conducted by Ulla-Britt Wennerholm, Sahlgrenska University, Obstetrics and Gynecology, Göteberg, Sweden; Anna-Karina Henningsen and Anja Pinborg, Rigshospitalet, Fertility Clinic, Köpenhamn, Denmark; Liv-Bente Romundstad, St. Olav's University Hospital, Obstetrics and Gynecology, Trodenheim, Norway; Rolv Skjaerven, Medical Birth Register, Bergen Norway; Karl Gösta Nygren, Sophiahemmet, Sophiahemmet, Stockhom, Sweden; Mika Gissler, National Inst. Health and Welfare, THL, Helsinki, Finland; Aila Tiitinen, Helsinki University Central Hospital, Obstetrics and Gynecology, Helsinki, Finland.


Story Source:

The above story is based on materials provided by Society for Maternal-Fetal Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Society for Maternal-Fetal Medicine. "Better outcome for frozen embryo replacement vs IVF." ScienceDaily. ScienceDaily, 11 February 2013. <www.sciencedaily.com/releases/2013/02/130211102215.htm>.
Society for Maternal-Fetal Medicine. (2013, February 11). Better outcome for frozen embryo replacement vs IVF. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/02/130211102215.htm
Society for Maternal-Fetal Medicine. "Better outcome for frozen embryo replacement vs IVF." ScienceDaily. www.sciencedaily.com/releases/2013/02/130211102215.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) — Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) — Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) — Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins